48 research outputs found
Tissue Factor/Factor FVII Complex Inhibitors in Cardiovascular Disease. Are Things Going Well?
Blood coagulation is a complex biological mechanism aimed to avoid bleeding in which a highly regulated and coordinated interplay of specific proteins and cellular components respond quickly to a vascular injury. However, when this mechanisms occurs in the coronary circulation, it has not a “protective” effect, but rather, it plays a pivotal role in determining acute coronary syndromes. Coagulation recognizes Tissue Factor (TF), the main physiological initiator of the extrinsic coagulation pathway, as its starter
Obesity and ischemic heart disease. Is there a link between wellness’ diseases?
Obesity, the most common nutritional disorder in Western countries, is usually associated to cardiovascular diseases. However, the precise molecular pathways underlying this close association remain poorly understood. Nowadays, the adipose tissue is considered as an endocrine organ able to produce substances called adipo(cyto)kines that have different effects on lipid metabolism, closely involved in metabolic syndrome, and cardiovascular risk. The increased cardiovascular risk can be related also to peculiar dysfunction in the endocrine activity of adipose tissue observed in obesity responsible of vascular impairment (including endothelial dysfunction), prothrombotic tendency, and low-grade chronic inflammation. The present review aims at providing an up-dated overview on the adipocytederived molecules potentially involved in cardiovascular pathophysiology
Molecular epidemiology of Usher syndrome in Italy
Purpose: Usher syndrome is an autosomal recessive disorder characterized by hearing and vision loss. Usher syndrome
is divided into three clinical subclasses (type 1, type 2, and type 3), which differ in terms of the severity and progression
of hearing loss and the presence or absence of vestibular symptoms. Usher syndrome is defined by significant genetic
heterogeneity, with at least 12 distinct loci described and 9 genes identified. This study aims to provide a molecular
epidemiology report of Usher syndrome in Italy.
Methods: Molecular data have been obtained on 75 unrelated Italian patients using the most up-to date technology
available for the screening of Usher syndrome gene mutations, i.e., the genotyping microarray developed by Asper Biotech
(Tartu, Estonia), which simultaneously investigates 612 different marker positions using the well established arrayed
primer extension methodology (APEX).
Results: Using this method, we found that 12% of cases (9 out of 75) harbored homozygous or compound heterozygous
mutations in the gene positions analyzed, whereas 20% (15 out of 75) of the patients were characterized by the presence
of only one mutated allele based on the positions analyzed. One patient was found to be compound heterozygous for
mutations in two different genes and this represents an example of possible digenic inheritance in Usher syndrome. A
total of 66.6% of cases (50 out of 75) were found to be completely negative for the presence of Usher syndrome gene
mutations in the detected positions. Mutations detected by the array were confirmed by direct sequencing.
Conclusions: These findings highlight the efficacy of the APEX-based genotyping approach in the molecular assessment
of Usher patients, suggesting the presence of alleles not yet identified and/or the involvement of additional putative genes
that may account for the pathogenesis of Usher syndrome
Comparison of the Sapien 3 versus the ACURATE neo valve system: A propensity score analysis
Objectives: To compare the outcomes of transfemoral ACURATE neo (NEO) and Sapien 3 (S3) patients in terms of device success and clinical safety outcomes using a propensity score analysis. Background: Differences in clinical outcomes between the latest-generation balloon-expandable S3 and self-expanding NEO in a “real-world transfemoral TAVI population” are still unclear. Methods: We compared up to 6 months clinical outcomes using a propensity s
Impact of baseline and newly acquired conduction disorders on need for permanent pacemakers with 3 consecutive generations of self-expanding transcatheter aortic heart valves
Introductions: We aimed to compare conduction dynamics and need for permanent pacemaker implantation (PPI) after CoreValve, Evolut R and PRO (transcatheter aortic valve replacement (TAVR)). Methods: Patients were stratified based on conduction at baseline; Cohort A had normal conduction, Cohort B had conduction abnormalities including atrioventricular (AV)-block, fascicular block or complete bundle branch block. Three different dynamic QRS-patterns were defined: stable QRS-duration, transient QRS-prolongation and persistent QRS-prolongation. We performed multivariable regression analysis to estimate the effect of the three separate transcatheter heart valves (THV's) on need for PPI at 30 days. Results: TAVR was performed with CoreValve (N = 113), Evolut R (N = 157) or Evolut PRO (N = 92). Conduction dynamics were similar between the different THVs. Overall, Evolut R and PRO showed a tendency towards less PPI compared to CoreValve (17% vs. 19% vs. 27%, P = 0.08), which was driven by a lower PPI rate in Cohort A (6% vs. 11% vs. 25%, P = 0.002). Need for PPI was restricted to patients with persistent QRS-prolongation in Cohort A (26/106) but did not correlate with conduction dynamics in Cohort B. In multivariable logistic regression analysis the use of Evolut R (OR 0.38, 95% CI 0.19–0.78, P = 0.008) and PRO (OR 0.41, 95% CI 0.19–0.91, P-value = 0.028) were independently associated with less need for PPI. Conclusion: The newer generations Evolut R and PRO were associated with less PPI compared to CoreValve. Acquired persistent conduction abnormalities predicted PPI after TAVR only in patients with normal conduction at baseline. Our findings may help identify eligible patients for early discharge after Evolut R/PRO TAVR
Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration
The safety and efficacy of gene therapy for inherited retinal diseases is being tested in humans affected with Leber's congenital amaurosis (LCA), an autosomal recessive blinding disease. Three independent studies have provided evidence that the subretinal administration of adeno-associated viral (AAV) vectors encoding RPE65 in patients affected with LCA2 due to mutations in the RPE65 gene, is safe and, in some cases, results in efficacy. We evaluated the long-term safety and efficacy (global effects on retinal/visual function) resulting from subretinal administration of AAV2-hRPE65v2. Both the safety and the efficacy noted at early timepoints persist through at least 1.5 years after injection in the three LCA2 patients enrolled in the low dose cohort of our trial. A transient rise in neutralizing antibodies to AAV capsid was observed but there was no humoral response to RPE65 protein. The persistence of functional amelioration suggests that AAV-mediated gene transfer to the human retina does not elicit immunological responses which cause significant loss of transduced cells. The persistence of physiologic effect supports the possibility that gene therapy may influence LCA2 disease progression. The safety of the intervention and the stability of the improvement in visual and retinal function in these subjects support the use of AAV-mediated gene augmentation therapy for treatment of inherited retinal diseases